S4: Application of human pluripotent stem cell-derived cardiomyocytes

Application of human pluripotent stem cell-derived cardiomyocytes for cell therapy and drug development

Application of human pluripotent stem cell-derived cardiomyocytes, OpenTox Asia 2017

Hyung-Min Chung 


Konkuk University School of Medicine


Director and Professor


Since the establishment of human pluripotent stem cells (hPSC), the capacity of hPSC to differentiate into three germ layer lineages has sparked considerable interest in the regenerative medicine community. In particular, the potential application of cardiomyocytes derived from hPSC is widely recognized in developing cell therapies for various types of heart diseases including myocardial infarction. Decades of strenuous research have come to fruition in recent years when human clinical trials using hPSC-cardiomyocytes have initiated. Such cell types could also be used for high-throughput screening for cardiotoxicity during drug discovery. The development of pharmaceutical therapeutics faces the difficult tasks of predicting safety outcomes of lead candidate drugs in the human because animal model based drug responsiveness is never congruent with those observed in the human. Revolutionary hPSC technologies have paved the way to develop human cell-based in vitro assays that could change the current drug discovery landscape by enhancing the likelihood of clinical success of drug candidates. In this presentation, we first describe and summarize our differentiation protocols for acquiring highly purified cardiomyocytes, and their therapeutic efficiency in animal models of myocardial infarction. We will also demonstrate how our differentiation protocols can be applied to generate cardiomyocytes from normal and disease patients’ hPSC to test their feasibility in drug and toxicity screening.